suPAR is a biomarker and therapeutic target for AKI
Catalytic iron is a biomarker
and therapeutic target in AKI
A common genetic variant in HO-1 predicts risk of AKI following cardiac surgery
Immune checkpoint inhibitors cause AKI through tubulo-interstitial nephritis
FGF23 is an early marker of AKI and death after cardiac surgery and in critically ill patients.
The Leaf Lab conducts patient-oriented research in acute kidney injury (AKI). Our goal is to develop novel approaches to prevent AKI, and to improve outcomes in patients who suffer from AKI. Read more about AKI.
Our research is highly collaborative and interdisciplinary and includes:
• Randomized trials
• Biomarker studies
NIH R01 Grant
May 1, 2019
David Leaf was awarded an R01 grant from the NIH/NHLBI for his proposal entitled, “Precision Medicine Approach to Vitamin D3 Administration in Critically Ill Patients.”
July 1, 2018
David Leaf was awarded a Carl W. Gottschalk Research Scholar Grant to study, “Hepcidin, Dysregulated Iron Homeostasis, and Anemia in Human AKI” from the American Society of Nephrology Foundation for Kidney Research.